Literature DB >> 2063771

The lymphomas: Hodgkin's disease and non-Hodgkin's lymphomas.

C Lindley1.   

Abstract

This review presents an overview of a heterogeneous group of disorders that fall under the general heading of lymphomas. Many specific subtypes and presentations exist; their presentations, treatments, and prognoses vary greatly. Patients with lymphomas are generally treated with external beam radiation therapy, chemotherapy, or a combination of these two modalities. The community pharmacist may play an important role in management of patients by recognizing and alleviating the distressing side effects of treatment. Unfortunately, prevention and early detection play little role in the management of lymphomas. The improvement in survival rates of patients with all but indolent NHL is a direct result of advances in chemotherapy.

Entities:  

Mesh:

Year:  1991        PMID: 2063771     DOI: 10.1016/s0160-3450(16)33731-x

Source DB:  PubMed          Journal:  Am Pharm        ISSN: 0160-3450


  2 in total

1.  Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.

Authors:  Shiloh M Martin; Robert T O'Donnell; David L Kukis; Craig K Abbey; Hayes McKnight; Julie L Sutcliffe; Joseph M Tuscano
Journal:  Mol Imaging Biol       Date:  2008-10-24       Impact factor: 3.488

2.  The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.

Authors:  Joseph M Tuscano; Yunpeng Ma; Shiloh M Martin; Jason Kato; Robert T O'Donnell
Journal:  Cancer Immunol Immunother       Date:  2011-02-24       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.